Individual alpha peak frequency tracks Alzheimer's disease progression: A longitudinal pilot study
Journal of Alzheimer’s Disease · 2026
DOI: 10.1177/13872877261476331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2026. Verfasst von Ruimin Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Electrical and Electronic Engineering, Faculty of Science and Engineering, Saga University, Saga, Japan. Hauptthemen laut MEDLINE: Alzheimer Disease, Disease Progression, Alpha Rhythm. Die Arbeit nennt 58 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Themen: Demenz
Abstract (Originalsprache)
Background
Early and accurate tracking of Alzheimer's disease (AD) progression is critical for timely intervention. However, electrophysiological biomarkers capable of capturing long-term neurodegenerative changes remain largely underexplored.
Objective
We investigated whether individual alpha peak frequency (IAPF), an electroencephalography (EEG)-derived measure of dominant neural oscillatory activity, could serve as a longitudinal biomarker of AD progression.
Methods
Twenty-seven patients with AD aged 63–91 years underwent annual EEG and cognitive assessments over 2–7 years. IAPF was extracted from eyes-closed resting-state EEG. Longitudinal associations among IAPF, Mini-Mental State Examination (MMSE) scores, age, and follow-up time were evaluated using repeated-measures correlation and linear mixed-effects models. Annual IAPF changes were compared with those of healthy controls (HC) aged 20–70 years, stratified by decade-based age subgroups. Longitudinal changes in relative spectral power were also analyzed.
Results
Patients with AD showed significant longitudinal declines in both IAPF and MMSE scores, with a positive longitudinal association between the two measures. Mixed-effects models indicated that these declines were better explained by follow-up time after accounting for baseline age than by age at assessment alone. Compared with all healthy-control age subgroups, patients with AD exhibited a significantly steeper annual IAPF decline. Relative theta power increased and alpha/beta power decreased over follow-up, consistent with spectral slowing. However, annualized spectral-power changes showed limited disease specificity, with significant AD–HC differences only for delta and alpha power relative to the oldest HC subgroup.
Conclusions
These findings support IAPF as a non-invasive, temporally sensitive, and clinically accessible biomarker for monitoring AD progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Electrical and Electronic Engineering, Faculty of Science and Engineering, Saga University, Saga, Japan.
- Department of Neurology, Minkodo Minohara Hospital, Fukuoka, Japan.
- National Hospital Organization, Hizen Psychiatric Center, Saga, Japan.
- Institute of Ocean Energy, Saga University, Saga, Japan.
ORCID-Profile: Ruimin Wang, Yoshitaka Matsuda, Satoru Goto
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Wang, R., Yamasaki, T., Mitsudo, T., Matsuda, Y., Goto, S., & Sugi, T. (2026). Individual alpha peak frequency tracks Alzheimer's disease progression: A longitudinal pilot study. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877261476331
Vancouver
Wang R, Yamasaki T, Mitsudo T, Matsuda Y, Goto S, Sugi T. Individual alpha peak frequency tracks Alzheimer's disease progression: A longitudinal pilot study. Journal of Alzheimer’s Disease. 2026. doi:10.1177/13872877261476331
BibTeX
@article{Wang2026,
author = {Wang, Ruimin and Yamasaki, Takao and Mitsudo, Takako and Matsuda, Yoshitaka and Goto, Satoru and Sugi, Takenao},
title = {Individual alpha peak frequency tracks Alzheimer's disease progression: A longitudinal pilot study},
journal = {Journal of Alzheimer’s Disease},
year = {2026},
doi = {10.1177/13872877261476331}
}
EUVIMED